Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Cybin Inc. CLXPF

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Secures IRB Approval to Commence Study of Psilocybin Formulation in Treatment of Major Depressive Disorder

Posted on May 18, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the Institutional Review Board (“IRB”) at the University of the West Indies Hospital in Jamaica has granted approval to commence the study of its … Continue reading →

Posted in Cybin Inc. CLXPF | Leave a comment

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update

Posted on May 14, 2021 by MissionIR

April analyst reports all point to a bright future for Cybin “CYBN is a true multi-molecule company that’s not being reflected in its valuation,” reports Stifel “With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the … Continue reading →

Posted in Cybin Inc. CLXPF | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Collaborates to Potentially Develop New Therapy for Treatment-Resistant Psychiatric Disorders

Posted on May 13, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently acquired Adelia Therapeutics, thereby adding CYB003 to its pipeline. It subsequently made an equally important move when it inked a drug-development agreement … Continue reading →

Posted in Cybin Inc. CLXPF | Leave a comment

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Looks to New Senior Management with Expertise in Development, Clinical Capabilities

Posted on May 10, 2021 by MissionIR

Company committed to building presence in U.S. and Europe to advance mission of improving mental health care New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry New leaders bring broad experience, deep insight to … Continue reading →

Posted in Cybin Inc. CLXPF | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) CEO to Present at Global Small Cap Conference

Posted on May 7, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that CEO Doug Drysdale will be presenting at the upcoming Benzinga Global Small Cap Conference. The conference, slated for Thursday, May 13, 2021, is designed to … Continue reading →

Posted in Cybin Inc. CLXPF, MissionIRNewsBreaks | Leave a comment

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Signs Drug-Development Agreement, One Step Closer to Effective Psychiatric Disorder Treatment 

Posted on May 5, 2021 by MissionIR

Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders Cybin looking to identify fast-acting, shorter-duration formulations of CYB003 Delivering CYB003 through Catalent ODT could provide significant benefits Cybin (NEO: CYBN) (OTCQB: CLXPF), a … Continue reading →

Posted in Cybin Inc. CLXPF | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Eyes Rapid Progress to Clinical Studies for Psychedelic Drug Candidates

Posted on May 3, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has completed key in-vitro and in-vivo research studies. The company recently announced completion of its 20th pre-clinical study and the progression of … Continue reading →

Posted in Cybin Inc. CLXPF | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces AUD Disorder Indication for Psychedelic Molecule CYB003

Posted on April 26, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has selected alcohol use disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. In the announcement, the company noted that its CYB003 … Continue reading →

Posted in Cybin Inc. CLXPF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Data Providing Strong Support to Advance Drug Development Candidates

Posted on April 21, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it has successfully demonstrated proof of concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of depression and addiction. According to … Continue reading →

Posted in Cybin Inc. CLXPF | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Establishes Clinical Advisory Board, to Present at Bloom Burton & Co. Health Care Investor Conference

Posted on April 19, 2021 by MissionIR

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced the formation of its clinical advisory board. Additions to the board include Maurizio Fava, MD, psychiatrist-in-chief in the Department of Psychiatry at Massachusetts General Hospital, … Continue reading →

Posted in Cybin Inc. CLXPF, MissionIRNewsBreaks | Leave a comment